業績

英文原著

1. Yoshimoto T, Oshima T, Fukada T, Imamura N, Nakanishi T, Ebisutani N, Morishita D, Mieno M, Nakai K, Sei H, Kitayama Y, Eda H, Okugawa T, Tomita T, Fukui H, Shinzaki S.
   Pegfilgrastim for the management of neutropenia during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer patients. Int J Clin Oncol. 2023 Dec 8. Online ahead of print.
2. Wong SY, Wellens J, Helmus D, Marlow L, Brann S, Martinez Pazos V, Weinberg A, Moran HR, McGregor C, Vermeire S, Watanabe K, Kamikozuru K, Ahuja V, Vermani S, Lindsay JO, Kingston A, Dutta U, Kaur H, Silverberg MS, Milgrom R, Chien Ng S, Mak JWY, Cadwell K, Thompson C, Colombel JF, Satsangi J; ICARUS-IBD Consortium.
   Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium.
   Inflamm Bowel Dis. 2023 Nov 2;29(11):1693–1705
3. Hirai M, Yanai S, Kunisaki R, Nishio M, Watanabe K, Sato T, Ishihara S, Anzai H, Hisabe T, Yasukawa S, Maeda Y, Takishima K, Ohno A, Shiga H, Uraoka T, Itoi Y, Ogata H, Takabayashi K, Yoshida N, Saito Y, Takamaru H, Kawasaki K, Esaki M, Tsuruoka N, Hisamatsu T, Matsumoto T.
   Effectiveness of endoscopic resection for colorectal neoplasms in ulcerative colitis: a multicenter registration study.
   Gastrointest Endosc. 2023 Nov;98(5):806-812.
4. Watanabe K, Nojima M, Nakase H, Sato T, Matsuura M, Aoyama N, Kobayashi T, Sakuraba H, Nishishita M, Yokoyama K, Esaki M, Hirai F, Nagahori M, Nanjo S, Omori T, Tanida S, Yokoyama Y, Moriya K, Maemoto A, Handa O, Ohmiya N, Tsuchiya K, Shinzaki S, Kato S, Uraoka T, Tanaka H, Takatsu N, Nishida A, Umeno J, Nakamura M, Mishima Y, Fujiya M, Tsuchida K, Hiraoka S, Okabe M, Toyonaga T, Matsuoka K, Andoh A, Hirota Y, Hisamatsu T; J-COMBAT study group.
   Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
   J Gastroenterol. 2023 Oct;58;(10):1015-1029.
5. Yamamoto T, Nakase H, Watanabe K, Shinzaki S, Takatsu N, Fujii T, Okamoto R, Matsuoka K, Yamada A, Kunisaki R, Matsuura M, Shiga H, Bamba S, Mikami Y, Shimoyama T, Motoya S, Torisu T, Kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Maemoto A, Murata Y, Yoshigoe S, Nagasaka S, Yajima T, Hisamatsu T.
   Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn’s Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn’s Disease (iCREST-CD).
   J Crohns Colitis. 2023 Aug 21;17(8):1193-1206.
6. Tomita T, Fukui H, Okugawa T, Nakanishi T, Mieno M, Nakai K, Eda H, Kitayama Y, Oshima T, Shinzaki S, Miwa H.
   Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn's Disease: A Prospective Pilot Study.
   J Clin Med. 2023 May 9;12(10):3368
7. Yoshihara T, Shinzaki S, Iijima H, Tsujii Y, Hayashi Y, Takehara T.
   Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease concerns about the different results obseved between two meta-analyses.
   J Gastroenterol Hepatol. 2023 May;38(5):830-832
8. Sato T, Uchino M, Takeuchi J, Fujihira Y, Shimizu K, Yokoyama K, Yagi S, Kaku K, Takashima Y, Ikenouchi M, Kojima K, Kawai M, Nagase K, Kamikozuru K, Yokoyama Y, Takagawa T, Ikeuchi H, Watanabe K, Shinzaki S.
   Short-term clinical evaluation of teduglutide for patients with Crohn’s disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.
   Clin Nutr. 2023 May;42(5):722-731
9. Tomita T, Fukui H, Morishita D, Maeda A, Makizaki Y, Tanaka Y, Ohno H, Oshima T, Miwa H. Diarrhea-predominant Irritable Bowel Syndrome-like Symptoms in Patients With Quiescent Crohn’s Disease:Comprehensive Analysis of Clinical Features and Intestinal Environment Including the Gut Microbiome, Organic Acids, and Intestinal Permeability.
   J Neurogastroenterol Motil. 2023 Jan 30;29(1):102-112.
10. Tomita T, Fukui H, Morishita D, Mori S, Oshima T, Shinzaki S, Miwa H.
    Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
    J Clin Med. 2022 Nov 22;11(23):6882.
11. Matsuoka K, Fujii T, Okamoto R, Yamada A, Kunisaski R, Matsuura M, Watanabe K, Shiga H, Takatsu N, Bamba S, Mikami Y, Yamamoto T, Shimoyama T, Motoya S, Trisu T, kobayashi T, Ohmiya N, Saruta M, Matsuda K, Matsumoto T, Nakase H, Maemoto A, Shinzaki S, Murata Y, Yoshigoe S, Sasaki A, Yajima T, Hisamatsu T.
    Characteristics of adult patients newly diagnosed with Crohn’s disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn’s disease in Japan (iCREST-CD).
    J Gastroenterol. 2022 Nov;57(11):867-878